Transport
Methodist Hospital Levelland
Methodist Hospital Levelland was paid $2.25M by Medicaid between Oct 2020 and Nov 2024, across 58 billing codes. Its largest line is 87502, Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets — 21% of everything it billed.
33Billing provider infoMETHODIST HOSPITAL LEVELLAND
LEVELLAND, TX 79336
LEVELLAND, TX 79336
33aNPI1225146400assigned 08/28/2006
33bProvider typeAmbulance
28Total paid$2.25M
24GClaims41,035
24DCodes billed58
24AFirst – last monthOct 2020 – Nov 2024
Compared with peers
Next to other Ambulance providers in Texas
Rank by total paid#21 of 184
Median peer was paid$197K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 896 | $48K | |
| 2021 | 8,300 | $348K | |
| 2022 | 13,540 | $763K | |
| 2023 | 12,432 | $714K | |
| 2024incomplete | 5,867 | $374K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 21% | 3,770 | 3,653 | $468K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 2,211 | 2,143 | $435K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 1,011 | 971 | $328K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 8.3% | 2,931 | 2,789 | $187K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 7.8% | 3,633 | 3,474 | $176K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6.0% | 2,707 | 2,626 | $135K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 5.1% | 808 | 773 | $115K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.7% | 2,371 | 1,206 | $60K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.2% | 124 | 119 | $50K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.9% | 148 | 139 | $42K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.2% | 768 | 742 | $28K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 5,229 | 4,654 | $27K |
46 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 303 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 3,820 | $26K |
| 80053 | Comprehensive metabolic panel | <1% | 2,492 | $18K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 29 | $17K |
| 86780 | <1% | 714 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,202 | $13K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 381 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 661 | $7K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 425 | $7K |
| 87807 | <1% | 277 | $6K | |
| 81003 | <1% | 1,802 | $6K | |
| 87150 | <1% | 110 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 79 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 47 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 70 | $3K |
| 86850 | <1% | 138 | $3K | |
| 83655 | <1% | 142 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 52 | $2K |
| 86762 | <1% | 79 | $2K | |
| 81001 | <1% | 707 | $2K | |
| 87486 | <1% | 29 | $1K | |
| 87581 | <1% | 29 | $1K | |
| 86735 | <1% | 62 | $1K | |
| 86765 | <1% | 62 | $1K | |
| 87340 | <1% | 82 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 46 | $1K |
| 84703 | <1% | 101 | $1K | |
| 84439 | <1% | 153 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 137 | $1K |
| 80050 | General health panel | <1% | 39 | $1K |
| 74018 | <1% | 16 | $1K | |
| 80061 | Lipid panel | <1% | 100 | $902.55 |
| 87081 | <1% | 222 | $695.51 | |
| 86901 | <1% | 138 | $621.13 | |
| 86900 | <1% | 138 | $621.13 | |
| 85018 | <1% | 163 | $596.14 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12 | $528.76 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $365.60 |
| 87070 | <1% | 43 | $226.37 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16 | $211.00 |
| 81000 | <1% | 48 | $206.20 | |
| 86580 | <1% | 16 | $192.08 | |
| 86592 | <1% | 15 | $121.42 | |
| 81025 | <1% | 14 | $73.39 | |
| 83880 | <1% | 14 | $31.90 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 87 | $0.01 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.